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Abstract
Introduction: Orbital lesions are rare, but are likely to become symptomatic and can impact on patients’ quality of life. Local
control is often difficult to obtain, because of proximity to critical structures. CyberKnife stereotactic robotic radiotherapy could
represent a viable treatment option. Materials and Methods: Data on patients treated for intraorbital lesions from solid
malignancies were retrospectively collected. All patients underwent treatment with CyberKnife system. We analyzed local
control, response rate, symptoms control, progression-free survival and overall survival, acute and late toxicity. Results: From
January 2012 to May 2017, 20 treatments on 19 patients were performed, with dose ranging from 24 to 35 Gy in 1 to 5 fractions,
prescribed at an average isodose line of 79.5% (range: 78-81). After a mean follow-up of 14.26 months (range: 0-58), overall
response rate was 75%, with 2 and 4 patients presenting a partial and complete response, respectively. Mean time to best
measured response was 15.16 months (range: 2-58). Thirteen patients were alive, with a local control rate of 79%. Mean time to
local progression was 5 months (range: 3-7). Three patients reported improvement in symptoms after treatment. Mean planning
target volume dose coverage was 97.2% (range: 93.5-99.7). Mean maximum dose (D max) to eye globe, optic nerve, optic chiasm,
and lens was 2380.8 cGy (range: 290-3921), 1982.82 cGy (range: 777.3-2897.8), 713.14 cGy (range: 219.5-2273), and 867.9 cGy
(range: 38-3118.5). Four patients presented acute toxicity. Conclusion: This current retrospective series demonstrated that
CyberKnife robotic stereotactic radiotherapy is a feasible and tolerable approach for intraorbital lesions.
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Introduction
Primary and secondary orbital lesions occur infrequently, but
they can represent an important issue in clinical practice related
to their propensity to become symptomatic and their impact on
patients’ quality of life. Furthermore, local control (LC) is
often difficult to obtain, because of proximity to critical
structures.1,2
Systemic therapies are a cornerstone for metastatic disease
treatment, but the integration with a local therapy, aimed to
reduce tumor bulk, could help to improve outcomes; Cyber-
Knife robotic radiotherapy could constitute a viable treatment
option for this kind of lesions.3,4
CyberKnife stereotactic body radiotherapy allows to
achieve steep dose gradients, with very high biological effec-
tive dose on target volumes and effective organs at risk (OAR)
sparing, thanks to its peculiar target spatial localization sys-
tem.5-7 This is of particular importance considering that optic
pathways and ocular adnexa have been shown to be prone to
late toxicity after stereotactic radiotherapy in older reports.7,8
In this article, a retrospective experience about patients con-
secutively treated with stereotactic robotic radiotherapy is pre-
sented, with the aim to explore the efficacy and tolerability of
this treatment option in this setting.
Materials and Methods
We retrospectively collected data on patients consecutively
treated for primary and metastatic intraorbital lesions from
solid malignancies at our institution. Intraorbital lesions were
defined as lesions located inside the orbital cavity, excluding
those strictly confined to orbital bone structures. All patients
underwent treatment with CyberKnife system (Accuray Inc;
Figure 1). Planning computed tomography (CT) with and with-
out contrast was obtained with 1.25 mm slice thikness using a
multislice scanner (Lightspeed 16 GE Medical Systems,
Wisconsin). Gross target volume was delineated on a
contrast-enhanced CT scan coregistered with diagnostic mag-
netic resonance imaging (MRI) to improve morphologic defi-
nition of the target. A 1-mm-isotropic expansion was added to
delineated target volume to take into account inter- and intra-
fractional uncertainties and obtain a planning target volume
(PTV). All treatment plans were elaborated on MULTIPLAN
treatment planning station (version 5.3). Dose constraints for
involved OARs were obtained from the American Association
of Physicists in Medicine report.9 Patients were treated in
supine position, with the use of a custom mask for immobiliza-
tion and reproducible setup. Intrafraction motion management
was performed by 6-dimensional skull tracking using 2 ortho-
gonal diagnostic kV X-ray sources mounted on treatment room
ceiling at a 45 angle to the perpendicular axis (Accuray). The
6D Skull Tracking System enables direct tracking of the bony
anatomy of the skull when treating intracranial lesions. Target
tracking and motion compensation were accomplished by
using image intensity and brightness differences between the
digital reconstructed radiography and live images. Simple
descriptive statistics were used to analyze LC, response rate,
Figure 1. Example of a CyberKnife treatment plan for an orbitary lesion.
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symptoms control, progression-free and overall survival,
acute and late adverse events, assessed using CTCAE scale
version 4.0.
Results
From January 2012 to May 2017, 20 treatments on 19 patients
were performed in our institute. Baseline characteristics are
highlighted in Table 1. Patients were treated with dose ranging
from 24 to 35 Gy in 1 to 5 fractions, prescribed at an average
isodose line of 79.5% (range: 78-81). Only one patient did not
complete the scheduled treatment due to declining performance
status. Overall, median volume of treated lesions was 11.82 cc
(range: 2.2-45.1), with an average PTV of 18.15 cc (range: 2.6-
70.85). After a mean follow-up of 14.26 months (range: 0-58),
overall response rate was 75%, with 2 and 4 patients presenting
a partial and complete response, respectively. Mean time to
best measured response was 15.16 months (range: 2-58). Thir-
teen patients were alive, with a LC rate of 79%. Mean time to
local progression was 5 months (range: 3-7). Retreatment with
CyberKnife was needed in one patient and exenteration in
another one after local progression. Fourteen patients reported
symptomatic lesions, while 5 and 3 patients had reduced visual
field or impaired visual acuity before treatment, respectively.
Overall, 3 patients reported improvement in symptoms after
treatment: one patient reported partial recovery of visual
acuity, the second pain decrease and reduced eye tearing, and
the third reported improvement in visual field and reduced
exophthalmos. About dosimetric data, mean PTV dose cover-
age was 97.2% (range: 93.5-99.7). Mean maximum dose (D
max) to homolateral eye globe, optic nerve, lens, and optic
chiasm was 2380.8 cGy (range: 290-3921), 1982.82 cGy
(range: 777.3-2897.8), 713.14 cGy (range: 219.5-2273), and
867.9 cGy (range: 38-3118.5), respectively. Four patients pre-
sented acute toxicity, defined as occurring within 3 months
after the end of treatment (2 cases of conjunctivitis, 2 transitory
orbital pain, 1 grade 2 xerophthalmia, and 1 grade 2 dermatitis).
No severe toxicity was reported at the end of the study period.
Discussion
Overall, data presented in this retrospective experience show
that robotic stereotactic radiotherapy using CyberKnife system
was effective and well tolerated in the study population. Three
previously published retrospective experiences confirmed that
this treatment strategy is a valuable option for intraorbital
lesions.10-12 Hirschbein et al reported data about 16 patients
treated with dose ranging from 10 to 25 Gy in 2 to 5 fractions:
12 patients had a postoperative MRI showing stable disease or
response to radiotherapy, with 5 complete responses (all
patients affected by intraorbital lymphoma). All patients
affected by pretreatment pain reported symptoms resolution.
Visual evaluation was performed in all patients after procedure:
15 and 13 patients reported stable visual field and visual acuity,
respectively, and improvement in these parameters was
reported in 3 patients.10 Another retrospective series was pub-
lished in 2010, presenting outcomes of 14 treated lesions in 13
patients. However, population included in this experience is not
directly comparable with the current analysis, considering that
patients were affected exclusively by periocular lymphoma,
and that ocular lesions (ie, lesions affecting retina, choroid, and
conjunctiva) were included. Lesions were treated with a mean
treatment dose of 1718 cGy (range: 1350-2250 cGy) in 3 to 5
fractions. Authors reported complete response in all cases, with
a favorable toxicity profile.11 The most recent analysis was
conducted on 16 orbital metastases from solid cancers, affect-
ing 14 patients, all treated with single fraction CyberKnife
radiosurgery, with dose ranging from 16.5 to 21 Gy. Results
showed that 4 patients had partial response, while 1 reported
complete response after treatment. Overall, stable disease or
response to treatment was documented in 87% of patients. One
of 3 patients reporting pretreatment reduction in visual acuity,
and 2 of 5 reporting persistent diplopia, had improvement of
these deficits after treatment. No serious adverse effects were
reported.12 Previous experiences and current series’ main char-
acteristics are summarized in Table 2.
Table 1. Baseline Features of Study Population.
Characteristic
Sex M: 9 (47%)
F: 10 (53%)
Age (mean) 58.4 years (34-85)
Performance status 0: 11 (58%)
1: 6 (31%)
2: 2 (11%)
Lesion Primary: 6 (32%)
Metastatic: 13 (68%)
Histology - Breast: 4 (21%)
- Sarcoma: 3 (16%)
- Lung cancer: 2 (11%)
- Basalioma: 2 (11%)
- Plasmocitoma: 2 (11%)
- Lymphoma: 1 (5%)
- Colon cancer: 1 (5%)
- Apocrine carcinoma: 1 (5%)
- HCC: 1 (5%)
- Adenoid cystic carcinoma: 1 (5%)
- Lacrimal gland adenocarcinoma:
1 (5%)
Side Right: 4 (21%)
Left: 13 (68%)
Bilateral: 2 (11%)
Intraorbital structure
involvement
Roof: 11 (58%)
Medial wall: 10 (53%)
Floor: 7 (37%)
Lateral wall: 8 (42%)
Previous surgery Yes: 5 (26%)
No: 14 (74%)
Symptomatic lesion Yes: 14 (74%)
No: 5 (26%)
Total 19 (100%)
Abbreviation: HCC, hepatocellular carcinoma.
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The current experience is the largest available in this setting.
Furthermore, mean follow-up time in this analysis (14.26
months) ensures higher reliability of late toxicity results.
Another important feature to highlight in the presented series
is the robust definition of target localization. As previously
stated, no ocular lesion was included (eg, choroidal lesions),
neither bone lesions affecting periorbital structures. Interest-
ingly, median volume of treated lesions in our experience is
larger, if compared to previous data from the literature, con-
firming that Cyberknife radiosurgery may be considered as a
treatment option for a wide range of target volumes. Vast
majority of patients included in the current series was treated
in 5 fractions, while other authors proposed a 16.5 to 25 Gy
monofractionated schedule.12 A direct comparison with other
experiences could be difficult, and reported adverse events are
uncommon in all available literature.10-12 Currently, no recom-
mendation exists about correct doses and fractionations in this
setting, and these should be carefully evaluated according to
proximity of critical structures, histology, and target lesion
volume. Due to challenges posed by normal tissue dose toler-
ance, other authors treated orbital lesions in their experiences
with techniques other than CyberKnife, mainly using Gamma
Knife.13 Recently, a novel IMRT prescription concept termed
simultaneous integrated protection (PTV-SIP) for quantifiable
and comparable dose prescription to targets very close to OARs
have been described.14,15 This planning technique was not
adopted in our series of patients, mainly due to the novelty of
this approach and the utilization of a fractionated schedule
(commonly consisting of 5 fractions).
However, prospective data are needed to establish standard
doses and fractionations to be recommended. Considering the
availability of new systemic therapies that can potentially bring
to a survival increase, some metastatic patients could become
long survivors; local progression in this setting would be a
critical issue, and given the strict necessity to respect OAR
constraints, a retreatment could be considered challenging in
clinical practice. In our series, one patient affected by apocrine
carcinoma who had previously undergone stereotactic
Table 2. Summary of Previous Literature Data.
Author, Year Design
Patients/
Lesions (n) Histologies Dose (Gy)/fr
Median Treated
Volume (cc) Outcome Adverse Events
Hirschbein
et al, 200810
Retrospective 16/16 - Pancreatic
adenocarcinoma
- Lymphoma
- Melanoma
- Graves disease
- Adenocarcinoma
NOS
- Chronic orbital
inflammation
- Breast cancer
- Salivary gland
- Meningioma
10-25/2-5 5.91 (1.01-30.63) ORR: 75%
Symptoms control:
100%
transient
nausea: 1
Herpes Zoster: 1
Bianciotto
et al, 201011
Retrospective 13/14 Lymphoma 13.50-22.5/3-5 14.55 (10.7-54) ORR:100% Dry eye: 2
Cataract: 1
Klingenstein
et al, 201212
Retrospective 14/16 -Prostate
-Breast
-Melanoma
-Pancreatic
adenocarcinoma
-Pharinx carcinoma
- Kidney
16.5-21/1 7 (0.2-35) ORR:87% None
Current
experience
Retrospective 19/20 Breast Sarcoma: 3
- Lung cancer
- Basalioma
- Plasmocitoma:
- Lymphoma
- Colon cancer
- Apocrine
carcinoma
- HCC
- Adenoid cystic
carcinoma
- Lacrimal gland
adenocarcinoma
24-35/1-5 11.82 (2.2-45.1) ORR: 75%
LC: 79%
Conjunctivitis: 2
Orbital pain: 2, 1
Xeroftalmia: 1
Dermatitis:1
Abbreviations: HCC, hepatocellular carcinoma; LC, local control; ORR, overall response rate.
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radiotherapy was treated again on the same orbital lesion with
25 Gy in a 5 fraction schedule. After a follow-up of 2 years, the
patient was alive, but the lesion was further progressed after
first treatment and surgically removed through ocular resec-
tion. However, no significant adverse event was reported and
this treatment strategy probably postponed surgery, providing a
benefit in this case. Thus, orbital retreatment could be recom-
mended in highly selected patients.
Limitations of this work are its retrospective nature, the low
number and the heterogeneity of included patients. However,
data presented here are in line with previous literature and
confirm the efficacy of stereotactic body radiotherapy in this
setting of patients, with a low number of adverse events.
Conclusion
Data from our retrospective series demonstrated that Cyber-
Knife robotic stereotactic radiotherapy is a feasible and toler-
able approach for intraorbital lesions, and should be considered
in clinical practice. However, prospective experiences, aimed
to tailor doses and fractionations on the basis of lesions’ dimen-
sion and localization, are needed to improve the therapeutic
ratio of this treatment strategy.
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